Neurofibromatosis Therapeutics Market Market : Global Industry Analysis and Opportunity Assessment, 2036

Future Market Insights

Neurofibromatosis Therapeutics Market

Key Insight

Neurofibromatosis type 1 (NF1) represents 60.7% of the disease type category, plexiform neurofibromas account for 37.1% of manifestation demand and hospitals hold 33.0% of end user sales in 2026. The neurofibromatosis therapeutics market was valued at USD 680.5 million in 2025 and is forecast to post an 8.4% CAGR between 2026 and 2036.

July 23, 2026

Anurag Sharma

250 Pages

Cite this Report

Neurofibromatosis Therapeutics Market

https://www.futuremarketinsights.com/reports/neurofibromatosis-therapeutics-market

License

Starting at US$ 5000

Buy Now

Summary ToC Infographics Competitive Analysis

Key Players

AstraZeneca PLC
Merck KGaA
Healx Ltd.
NFlection Therapeutics, Inc.
Pasithea Therapeutics Corp.

Methodology

Member of

Greater New York Chamber of Commerce

Recognized by

Awarded by

SILVER STEVIE® WINNER

Asia Pacific Stevie Awards - 2023

BRONZE STEVIE® Award

20th annual IBAs

Quick Contact

Chat on Whatsapp + 44 20 3769 9709 + 1 347 918 3531 Contact By Email

Get Free Sample PDF

Neurofibromatosis Therapeutics Market

Key Players

Similar Industry Reports